Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 3 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 4 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 5 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 6 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 7 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 8 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 9 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 10 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 11 / 12



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Research ID:

Event date: __ __ __ __ - __ __- __ __

Recipient Data Questions: 1 - 13

Ethnicity1

Hispanic or Latino

Not Hispanic or Latino

Not applicable (not a resident of the USA)

Unknown

Race (check all that apply)

White

Black or African American

Asian

American Indian or Alaska Native

Native Hawaiian or Other Pacific Islander

Not reported

Unknown

2

Has the recipient signed an IRB / Ethics Committee-approved consent form for submitting research data to the CIBMTR?3

Yes (patient consented)

No (patient declined)

Not approached

Not applicable

Date form was signed:4 __ __ __ __ - __ __- __ __

Is the recipient participating in a cellular therapy clinical trial?

yes no

5

Clinical Trials (1) Questions: 6 - 11

Study sponsor6

BMT CTN

RCI BMT

USIDNET

COG

Corporate / Industry

EudraCT

UMIN

Investigator initiated

Other

Specify corporate / industry sponsor name:7

Specify EudraCT number:8

Specify UMIN number:9

Specify other sponsor:10

Specify the ClinicalTrials.gov identification number:11

Is the recipient receiving cellular therapy outside the context of a clinical trial?

Yes No

12

Specify the reason for not being on a clinical trial (check all that apply)

Institutional guidelines / standard treatment

Hospital exemption

Compassionate use

13

Cellular Therapy and HCT History Questions: 14 - 28

Is this the first application of cellular therapy (non-HCT)?14

Yes

No (recipient has previously been treated using cellular therapy)

Unknown

Were all prior cellular therapies (non-HCT) reported to the CIBMTR?

Yes No Unknown

15

Specify the number of prior cellular therapies:16

Prior Cellular Therapies (1) Questions: 17 - 22

Date of the prior cellular therapy:17 __ __ __ __ - __ __- __ __ Date estimated

Was the cellular therapy performed at a different institution?

Yes No

18

Name:19

City:

State:

Country:

Specify the indication for the prior cellular therapy20

Promote stem cell engraftment (e.g. co-infusion with HCT)

Suboptimal donor chimerism (post-HCT)

Immune reconstitution (post-HCT)

GVHD prophylaxis (with HCT)

GVHD treatment (post-HCT)

Prevent disease relapse (post-HCT)

Relapsed, persistent or progressive disease (post-HCT)

Infection treatment

Infection prophylaxis

B cell lymphoproliferative disorder (PTLD, EBV lymphoma)

Autoimmune disease

Cardiovascular disease

Musculoskeletal disorder

Neurologic disease

Ocular disease

Pulmonary disease

Solid tumor

Malignant hematologic disorder

Non-malignant disorder

Unknown

Other indication

Specify other indication:21

What was the cell source for the prior cellular therapy? (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

22

Has the recipient ever had a prior HCT?

Yes No Unknown

23

Were all prior HCTs reported to the CIBMTR?

Yes No Unknown

24

Prior HCTs (1) Questions: 25 - 28

Date of the prior HCT:25 __ __ __ __ - __ __- __ __

Was the HCT performed at a different institution?

Yes No

26

Name:27

City:

State:

Country:

Specify the HSC source(s) for the prior HCT (check all that apply)

Autologous

Allogeneic, unrelated

Allogeneic, related

28

Product Identification Questions: 29 - 46

Specify the total number of products: (per protocol) (as part of this course of cellular therapy)29

Is the product genetically modified?

Yes No

30

Donor Information (1) Questions: 31 - 43

Specify the cell source31

Autologous

Allogeneic, unrelated

Allogeneic, related

Specify the related donor type32

Syngeneic (monozygotic twin)

HLA-identical sibling (may include non-monozygotic twin)

HLA-matched other relative

HLA-mismatched relative

Was this donor used for any prior cellular therapies or HCT? (for this recipient)

Yes No Unknown

33

What is the tissue source of the cellular product? (check all that apply)

Bone marrow

Cord blood unit

Peripheral blood

Adipose tissue

Amniotic fluid

Cardiac tissue

Hepatic tissue

Neuronal tissue

Ophthalmic tissue

Pancreatic tissue

Placenta

Tumor

Umbilical cord

Other tissue source

Unknown

34

Specify other tissue source:35

What is the cell type? (Check all that apply)

Lymphocytes (unselected)

CD4+ lymphocytes

CD8+ lymphocytes

Cytotoxic T lymphocytes (CTLs)

Natural killer cells (NK cells)

Dendritic cells / tumor cell hybridomas

Mesenchymal stromal stem cells (MSCs)

Unspecified mononuclear cells

Endothelial progenitor cells

Human umbilical cord perivascular (HUCPV) cells

Cardiac progenitor cells

Islet cells

Oligodendrocytes

Other cell type

36

(tumor vaccines)

Specify other cell type:37

Where was the cellular therapy product manufactured / processed?38

Pharmaceutical / biotech company

Cell processing laboratory off site

Cell processing laboratory at the same center as the product is being infused

Other site

Specify other site:39

Specify pharmaceutical / biotech company40

Atara Biotherapeutics

Bellicum Pharmaceuticals

Bluebird Bio

Celgene

Juno Therapeutics

Kite Pharma

Mesoblast

Novartis

Other pharmaceutical company

Name:41

City:

State:

Country:

Name of product42

Tisagenlecleucel (Kymriah®)

Axicabtagene Ciloleucel (Yescarta®)

Other product

Specify other product:43

Is a subsequent HCT part of the overall treatment protocol?

Yes No

44

Specify the HCT type

Autologous Allogeneic

45

Specify the circumstances in which the subsequent HCT will be performed46

Regardless of response to cellular therapy

Only if the patient responds to cellular therapy

Only if the patient fails to respond or has an incomplete response

Indication for Cellular Therapy Questions: 47 - 60

Is the cellular therapy being given for prevention?

Yes No

47

Reason for prevention48

GVHD prophylaxis (with HCT)

Prevent disease relapse (post-HCT)

Infection prophylaxis

Indication for cellular therapy49

Suboptimal donor chimerism (Post-HCT)

Immune reconstitution (Post-HCT)

GVHD treatment (Post-HCT)

Malignant hematologic disorder - Also complete CIBMTR Form 2402

Non-malignant disorder - Also complete CIBMTR Form 2402

Solid tumor - Also complete CIBMTR Form 2402

Cardiovascular disease

Musculoskeletal disease

Neurologic disease

Ocular disease

Pulmonary disease

Infection treatment

Other indication

Date of diagnosis:50 __ __ __ __ - __ __- __ __

Specify cardiovascular disease51

AMI, acute myocardial infarction (701)

Chronic coronary artery disease (ischemic, cardiomyopathy) (702)

Heart failure (non-ischemic etiology) (703)

Other cardiovascular disease (709)

Limb ischemia (710)

Thromboangitis obliterans (711)

Other peripheral vascular disease (719)

Specify other cardiovascular disease:52

Specify other peripheral vascular disease:53

Specify musculoskeletal disorder54

Avascular necrosis of femoral head (721)

Osteoarthritis (722)

Osteogenesis imperfecta (723)

Traumatic joint injury (724)

Other musculoskeletal disorder (729)

Specify other musculoskeletal disorder:55

Specify neurologic disease56

Acute cerebral vascular ischemia (731)

ALS, amiotrophic lateral sclerosis (732)

Parkinson disease (733)

Spinal cord injury (734)

Cerebral palsy (753)

Congenital hydrocephalus (754)

Myasthenia gravis (601)

Duchenne muscular dystrophy (735)

Other neurologic disease (749)

Specify other neurologic disease:57

Specify ocular disease:58

Specify pulmonary disease:59

Specify other indication:60

Infection Questions: 61 - 67

61

62

63

64

65

66

Specify other organism:67

Disease Assessment at Last Evaluation Prior to Cellular Therapy Questions: 68 - 93

Was the disease assessed prior to the cellular therapy?

Yes No

68

Was the disease status assessed by molecular testing? (e.g. PCR)

Yes No Not Applicable

69

Date sample collected:70 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

71

Was the status considered a disease relapse or progression?

yes no

72

Was the disease status assessed via flow cytometry? (immunophenotyping)

Yes No Not Applicable

73

Date sample collected:74 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

75

Was the status considered a disease relapse or progression?

yes no

76

Was the disease status assessed by cytogenetic testing? (karyotyping or FISH)

Yes No Not Applicable

77

Was the disease status assessed via karyotyping?

Yes No Not Applicable

78

Date sample collected:79 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

80

Was the status considered a disease relapse or progression?

yes no

81

Was the disease status assessed via FISH?

Yes No Not Applicable

82

Date sample collected:83 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

84

Was the status considered a disease relapse or progression?

yes no

85

Was the disease status assessed by radiological assessment? (e.g. PET, MRI, CT)

Yes No Not Applicable

86

Date assessed:87 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

88

Was the disease status assessed by clinical / hematologic assessment?

yes no

89

Date assessed:90 __ __ __ __ - __ __- __ __

Was disease detected?

yes no

91

What was the recipient's disease status immediately prior to the cellular therapy?92

Complete remission (CR)

Not in complete remission

Date assessed:93 __ __ __ __ - __ __- __ __

Systemic Therapy Prior to Cellular Therapy Questions: 94 - 249

Was systemic therapy given immediately prior to cellular therapy as part of the cellular therapy protocol?

yes no

94

Date started:95 __ __ __ __ - __ __- __ __

Specify the reason for which the systemic therapy was given per protocol96

Lympho-depleting therapy

Reduction of tumor burden

Other reason

Specify other reason:97

ALG, ALS, ATG, ATS

yes no

98

Total dose:99 mg

Date started:100 __ __ __ __ - __ __- __ __

Specify source101

ATGAM (horse)

ATG - Fresenius (rabbit)

Thymoglobulin (rabbit)

Other

Specify other source:102

Anthracycline

Yes No

103

Daunorubicin (Cerubidine)

yes no

104

Total dose:105 mg

Date started:106 __ __ __ __ - __ __- __ __

Doxorubicin (Adriamycin)

yes no

107

Total dose:108 mg

Date started:109 __ __ __ __ - __ __- __ __

Idarubicin (Idamycin)

yes no

110

Total dose:111 mg

Date started:112 __ __ __ __ - __ __- __ __

Rubidazone

Yes No

113

Total dose:114 mg

Date started:115 __ __ __ __ - __ __- __ __

Other anthracycline

Yes No

116

Specify other anthracycline:117

Total dose:118 mg

Date started:119 __ __ __ __ - __ __- __ __

Bleomycin (BLM, Blenoxane)

yes no

120

Total dose:121 mg

Date started:122 __ __ __ __ - __ __- __ __

Busulfan (Myleran)

Yes No

123

Total dose:124 mg

Date started:125 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

126

Carboplatin

yes no

127

Total dose:128 mg

Date started:129 __ __ __ __ - __ __- __ __

Were pharmacokinetics performed to determine drug dosing?

Yes No

130

Specify the target AUC:131 mg/mL/minute

Cisplatin (Platinol, CDDP)

yes no

132

Total dose:133 mg

Date started:134 __ __ __ __ - __ __- __ __

Cladribine (2-CdA, Leustatin)

yes no

135

Total dose:136 mg

Date started:137 __ __ __ __ - __ __- __ __

Corticosteroids

yes no

138

Methylprednisolone (Solu-Medrol)

Yes No

139

Total dose:140 mg

Date started:141 __ __ __ __ - __ __- __ __

Prednisone

Yes No

142

Total dose:143 mg

Date started:144 __ __ __ __ - __ __- __ __

Dexamethasone

yes no

145

Total dose:146 mg

Date started:147 __ __ __ __ - __ __- __ __

Other corticosteroid

Yes No

148

Specify other corticosteroid:149

Total dose:150 mg

Date started:151 __ __ __ __ - __ __- __ __

Cyclophosphamide (Cytoxan)

yes no

152

Total dose:153 mg

Date started:154 __ __ __ __ - __ __- __ __

Cytarabine (Ara-C)

yes no

155

Total dose:156 mg

Date started:157 __ __ __ __ - __ __- __ __

Etoposide (VP-16, VePesid)

yes no

158

Total dose:159 mg

Date started:160 __ __ __ __ - __ __- __ __

Fludarabine (Fludara)

yes no

161

Total dose:162 mg

Date started:163 __ __ __ __ - __ __- __ __

Ifosfamide (Ifex)

yes no

164

Total dose:165 mg

Date started:166 __ __ __ __ - __ __- __ __

Intrathecal therapy (chemotherapy)

yes no

167

Intrathecal cytarabine (IT Ara-C)

Yes No

168

Total dose:169 mg

Date started:170 __ __ __ __ - __ __- __ __

Intrathecal methotrexate (IT MTX)

yes no

171

Total dose:172 mg

Date started:173 __ __ __ __ - __ __- __ __

Intrathecal thiotepa

Yes No

174

Total dose:175 mg

Date started:176 __ __ __ __ - __ __- __ __

Other intrathecal drug

Yes No

177

Specify other intrathecal drug:178

Total dose:179 mg

Date started:180 __ __ __ __ - __ __- __ __

Melphalan (L-PAM, Alkeran)

yes no

181

Total dose:182 mg

Date started:183 __ __ __ __ - __ __- __ __

Specify administration

Oral IV Both

184

Mitoxantrone (Novantrone)

yes no

185

Total dose:186 mg

Date started:187 __ __ __ __ - __ __- __ __

Monoclonal antibody (mAb)

Yes No

188

Radio labeled mAb

Yes No

189

Total dose of radioactive component:190 mCi MBq

Date started:191 __ __ __ __ - __ __- __ __

Tositumomab (Bexxar)

yes no

192

Ibritumomab tiuxetan (Zevalin)

yes no

193

Other radio labeled mAb

Yes No

194

Specify other radio labeled mAb:195

Alemtuzumab (Campath)

yes no

196

Total dose:197 mg

Date started:198 __ __ __ __ - __ __- __ __

Rituximab (Rituxan, anti CD20)

yes no

199

Total dose:200 mg

Date started:201 __ __ __ __ - __ __- __ __

Gemtuzumab (Mylotarg, anti-CD33)

yes no

202

Total dose:203 mg

Date started:204 __ __ __ __ - __ __- __ __

Other mAb

yes no

205

Specify other mAb:206

Total dose:207 mg

Date started:208 __ __ __ __ - __ __- __ __

Nitrosourea

Yes No

209

Carmustine (BCNU, Gliadel)

yes no

210

Total dose:211 mg

Date started:212 __ __ __ __ - __ __- __ __

CCNU (Lomustine)

Yes No

213

Total dose:214 mg

Date started:215 __ __ __ __ - __ __- __ __

Other nitrosourea

Yes No

216

Specify other nitrosourea:217

Total dose:218 mg

Date started:219 __ __ __ __ - __ __- __ __

Paclitaxel (Taxol, Xyotax)

Yes No

220

Total dose:221 mg

Date started:222 __ __ __ __ - __ __- __ __

Teniposide (VM26)

yes no

223

Total dose:224 mg

Date started:225 __ __ __ __ - __ __- __ __

Thiotepa

Yes No

226

Total dose:227 mg

Date started:228 __ __ __ __ - __ __- __ __

Treosulfan

Yes No

229

Total dose:230 mg

Date started:231 __ __ __ __ - __ __- __ __

Tyrosine kinase inhibitors (TKI)

yes no

232

Dasatinib (Sprycel)

yes no

233

Total dose:234 mg

Date started:235 __ __ __ __ - __ __- __ __

Imatinib mesylate (STI571, Gleevec)

yes no

236

Total dose:237 mg

Date started:238 __ __ __ __ - __ __- __ __

Nilotinib (AMN107, Tasigna)

yes no

239

Total dose:240 mg

Date started:241 __ __ __ __ - __ __- __ __

Other tyrosine kinase inhibitor

Yes No

242

Specify other tyrosine kinase inhibitor:243

Total dose:244 mg

Date started:245 __ __ __ __ - __ __- __ __

Other drug

Yes No

246

Specify other drug:247

Total dose:248 mg

Date started:249 __ __ __ __ - __ __- __ __

Functional Status Questions: 250 - 252

What scale was used to determine the recipient’s functional status prior to the cellular therapy250

Karnofsky (recipient age ≥ 16 years)

Lansky (recipient age ≥ 1 and < 16 years)

Karnofsky Scale (recipient age ≥ 16 years)251

Lansky Scale (recipient age ≥ 1 and < 16 years)252

Comorbid Conditions Questions: 253 - 311

Were there clinically significant co-existing diseases or organ impairment at time of patient assessment prior to preparative regimen? Source: Blood, 2005 Oct 15;106(8):2912-2919

yes no

253

Arrhythmia - For example, any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment

yes no Unknown

254

Cardiac - Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart
failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test

yes no Unknown

255

Cerebrovascular disease - Any history of transient ischemic attack, subarachnoid hemorrhage or cerebrovascular accident

yes no Unknown

256

Diabetes - Requiring treatment with insulin or oral hypoglycemics in the last 4 weeks but not diet alone

yes no Unknown

257

Heart valve disease - Except asymptomatic mitral valve prolapse

yes no Unknown

258

Hepatic, mild ­ Chronic hepatitis, bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the
time of transplant OR any history of hepatitis B or hepatitis C infection

yes no Unknown

259

Hepatic, moderate / severe ­ Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal

yes no Unknown

260

Infection - For example, documented infection, fever of unknown origin, or pulmonary nodules requiring continuation of antimicrobial treatment after day 0

yes no Unknown

261

Inflammatory bowel disease ­ Any history of Crohn’s disease or ulcerative colitis requiring treatment

yes no Unknown

262

Obesity - Patients with a body mass index > 35 kg/m2  prior to the start of conditioning

yes no Unknown

263

Peptic ulcer - Any history of peptic ulcer confirmed by endoscopy and requiring treatment

yes no Unknown

264

Psychiatric disturbance - For example, depression, anxiety, bipolar disorder or schizophrenia requiring psychiatric consult or treatment in the last 4 weeks

yes no Unknown

265

Pulmonary, moderate - Corrected diffusion capacity of carbon monoxide and/or FEV1 66-80% or dyspnea on slight activity at transplant

yes no Unknown

266

Pulmonary, severe - Corrected diffusion capacity of carbon monoxide and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant

yes no Unknown

267

Renal, moderate / severe ­ Serum creatinine > 2 mg/dL or > 177 µmol/L or on dialysis at transplant, OR prior renal transplantation

yes no Unknown

268

Rheumatologic - For example, any history of systemic lupus erythmatosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia
rheumatica requiring treatment (do NOT include degenerative joint disease, osteoarthritis)

yes no Unknown

269

Solid tumor, prior ­ Treated at any time point in the patient’s past history, excluding non­melanoma skin cancer, leukemia, lymphoma or multiple myeloma

yes no Unknown

270

Breast cancer

yes no

271

Year of diagnosis:272

Central nervous system (CNS) malignancy (glioblastoma, astrocytoma)

yes no

273

Year of diagnosis:274

Gastrointestinal malignancy (colon, rectum, stomach, pancreas, intestine)

yes no

275

Year of diagnosis:276

Genitourinary malignancy (kidney, bladder, ovary, testicle, genitalia, uterus, cervix)

yes no

277

Year of diagnosis:278

Lung cancer

yes no

279

Year of diagnosis:280

Melanoma

yes no

281

Year of diagnosis:282

Oropharyngeal cancer (tongue, buccal mucosa)

yes no

283

Year of diagnosis:284

Sarcoma

yes no

285

Year of diagnosis:286

Thyroid cancer

yes no

287

Year of diagnosis:288

Other co-morbid condition

yes no Unknown

289

Specify other co-morbid condition:290

Was there a history of malignancy (hematologic or non-melanoma skin cancer) other than the primary disease for which this infusion is being performed?

yes no

291

Acute myeloid leukemia (AML / ANLL)

yes no

292

Year of diagnosis:293

Other leukemia, including ALL

yes no

294

Year of diagnosis:295

Specify leukemia:296

Clonal cytogenetic abnormality without leukemia or MDS

yes no

297

Year of diagnosis:298

Hodgkin disease

yes no

299

Year of diagnosis:300

Lymphoma or lymphoproliferative disease

yes no

301

Year of diagnosis:302

Was the tumor EBV positive?

yes no

303

Other skin malignancy (basal cell, squamous)

yes no

304

Year of diagnosis:305

Specify other skin malignancy:306

Myelodysplasia (MDS) / myeloproliferative (MPN) disorder

yes no

307

Year of diagnosis:308

Other prior malignancy

yes no

309

Year of diagnosis:310

Specify other prior malignancy:311

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

This form must be completed for all recipients of non-HCT cellular products.  For recipients of hematopoietic cell transplants, complete a form 2400 - Pre-Transplant Essential
Data.

This form reflects baseline recipient data for one course of cellular therapy.

Specify the institution that performed the prior cellular therapy:

HCT History

Specify the institution that performed the prior HCT:

Specify the institution / company where the cellular product was manufactured:

Planned HCT

Cardiovascular disease

Musculoskeletal

Neurologic Disease

Ocular

Pulmonary

Other

Specify organism code(s):

Specify the method(s) of disease detection below.  For each method used, if the result was positive report the first date the disease was detected; if the result was negative
report the last date the method was used prior to cellular therapy. 

Specify radio labeled mAb:

Specify the functional status of the recipient immediately prior to the cellular therapy:

This section to be completed for malignant hematologic disorders and solid tumor indications.

Specify which malignancy(ies) occurred:

Center: CRID: 

Form 4000 R5.0: Cellular Therapy Essential Data Pre-Infusion Form

CIBMTR Form 4000 revision 5.0 last updated Monday, January 29, 2018
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 12 / 12